Featured Articles

  1. Patient Data Now Has Borders. Does Your Life Sciences Strategy? 5/22/2026

    As patient data rules tighten globally, life sciences companies should treat data sovereignty as a strategic opportunity to improve trial operations and partnerships.

  2. Why The Best Biotech Leaders Take It Personally 5/20/2026

    Personal investment isn’t a liability in biotech leadership, but rather, a competitive advantage, writes Lisa Ricciardi, CEO of Cognition Therapeutics.

  3. Beyond GLP-1s: Competing In The Era Of Consumerized Therapeutics 5/15/2026

    GLP-1 therapies created a consumer-driven market for pharmaceuticals that pairs digital access, partnerships, and retention tools with traditional launch models.

  4. A Door Ajar: FDA's Final SIUU Guidance And Off-Label Communications 5/13/2026

    FDA’s final SIUU guidance loosens some off-label communication rules, but drugmakers still face strict compliance demands to stay within the safe harbor. 

  5. 5 Critical Risks With The FDA's Real-Time Trial Monitoring 5/8/2026

    Life science legal experts Kimberly Chew and Odette Hauke cover the FDA proof-of-concept real-time clinical trials (RTCTs) and expose five major issues that must be addressed before the pilot expands.

  6. From Copilot To Autopilot: Why Biopharma Must Stop Renting Its Future 5/5/2026

    With AI, the tools are ready and the budgets are allocated, but they are flowing to the wrong places, write Romi Singh, Ph.D. and Jared R. Auclair, Ph.D. 

  7. How Commercial Leaders Can Optimize Their Relationships With The Board 4/30/2026

    The commercial leader/board dynamic will matter even more as pricing pressures and policy complexity increase, writes Beren Therapeutics' Bennett Smith.

  8. The East Is Ready: A New Axis Of Pharmaceutical Innovation 4/27/2026

    For Western pharmaceutical leaders, the question is no longer whether to engage Asia, but how to integrate its capabilities into core operating models. 

  9. Why Europe's Scientific Edge Still Struggles To Attract Global Capital 4/22/2026

    European biotech needs specialized capital and stronger continuity across funding stages to get to the next level, writes NUAgo Therapeutics CEO Robert Schickel, Ph.D.

  10. U.S. Pharma Tariffs And MFN Become Law After April 2 Update 4/15/2026

    Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them.